151 related articles for article (PubMed ID: 31816138)
21. Rapid Identification of Novel Allosteric PRC2 Inhibitors.
Read JA; Tart J; Rawlins PB; Gregson C; Jones K; Gao N; Zhu X; Tomlinson R; Code E; Cheung T; Chen H; Kawatkar SP; Bloecher A; Bagal S; O'Donovan DH; Robinson J
ACS Chem Biol; 2019 Oct; 14(10):2134-2140. PubMed ID: 31525019
[TBL] [Abstract][Full Text] [Related]
22. Small Molecule Approaches for Targeting the Polycomb Repressive Complex 2 (PRC2) in Cancer.
Martin MC; Zeng G; Yu J; Schiltz GE
J Med Chem; 2020 Dec; 63(24):15344-15370. PubMed ID: 33283516
[TBL] [Abstract][Full Text] [Related]
23. EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex.
Hsu JH; Rasmusson T; Robinson J; Pachl F; Read J; Kawatkar S; O' Donovan DH; Bagal S; Code E; Rawlins P; Argyrou A; Tomlinson R; Gao N; Zhu X; Chiarparin E; Jacques K; Shen M; Woods H; Bednarski E; Wilson DM; Drew L; Castaldi MP; Fawell S; Bloecher A
Cell Chem Biol; 2020 Jan; 27(1):41-46.e17. PubMed ID: 31786184
[TBL] [Abstract][Full Text] [Related]
24. Identification of SET/EED dual binders as innovative PRC2 inhibitors.
Catalano R; Maruca A; Rocca R; Tassone P; Panzarella G; Costa G; Ortuso F; Alcaro S
Future Med Chem; 2022 May; 14(9):609-621. PubMed ID: 35348013
[No Abstract] [Full Text] [Related]
25. Split luciferase-based biosensors for characterizing EED binders.
Li L; Feng L; Shi M; Zeng J; Chen Z; Zhong L; Huang L; Guo W; Huang Y; Qi W; Lu C; Li E; Zhao K; Gu J
Anal Biochem; 2017 Apr; 522():37-45. PubMed ID: 28111304
[TBL] [Abstract][Full Text] [Related]
26. Inactivation of Eed impedes MLL-AF9-mediated leukemogenesis through Cdkn2a-dependent and Cdkn2a-independent mechanisms in a murine model.
Danis E; Yamauchi T; Echanique K; Haladyna J; Kalkur R; Riedel S; Zhu N; Xie H; Bernt KM; Orkin SH; Armstrong SA; Neff T
Exp Hematol; 2015 Nov; 43(11):930-935.e6. PubMed ID: 26118502
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of EED Inhibitors as a Class of PRC2-Targeted Small Molecules for HIV Latency Reversal.
Turner AW; Dronamraju R; Potjewyd F; James KS; Winecoff DK; Kirchherr JL; Archin NM; Browne EP; Strahl BD; Margolis DM; James LI
ACS Infect Dis; 2020 Jul; 6(7):1719-1733. PubMed ID: 32347704
[TBL] [Abstract][Full Text] [Related]
28. Propagation of trimethylated H3K27 regulated by polycomb protein EED is required for embryogenesis, hematopoietic maintenance, and tumor suppression.
Ueda T; Nakata Y; Nagamachi A; Yamasaki N; Kanai A; Sera Y; Sasaki M; Matsui H; Honda Z; Oda H; Wolff L; Inaba T; Honda H
Proc Natl Acad Sci U S A; 2016 Sep; 113(37):10370-5. PubMed ID: 27578866
[TBL] [Abstract][Full Text] [Related]
29. EED orchestration of heart maturation through interaction with HDACs is H3K27me3-independent.
Ai S; Peng Y; Li C; Gu F; Yu X; Yue Y; Ma Q; Chen J; Lin Z; Zhou P; Xie H; Prendiville TW; Zheng W; Liu Y; Orkin SH; Wang DZ; Yu J; Pu WT; He A
Elife; 2017 Apr; 6():. PubMed ID: 28394251
[TBL] [Abstract][Full Text] [Related]
30. Discovery of the Clinical Candidate MAK683: An EED-Directed, Allosteric, and Selective PRC2 Inhibitor for the Treatment of Advanced Malignancies.
Huang Y; Sendzik M; Zhang J; Gao Z; Sun Y; Wang L; Gu J; Zhao K; Yu Z; Zhang L; Zhang Q; Blanz J; Chen Z; Dubost V; Fang D; Feng L; Fu X; Kiffe M; Li L; Luo F; Luo X; Mi Y; Mistry P; Pearson D; Piaia A; Scheufler C; Terranova R; Weiss A; Zeng J; Zhang H; Zhang J; Zhao M; Dillon MP; Jeay S; Qi W; Moggs J; Pissot-Soldermann C; Li E; Atadja P; Lingel A; Oyang C
J Med Chem; 2022 Apr; 65(7):5317-5333. PubMed ID: 35352560
[TBL] [Abstract][Full Text] [Related]
31. Recent strategies targeting Embryonic Ectoderm Development (EED) for cancer therapy: Allosteric inhibitors, PPI inhibitors, and PROTACs.
Zhao Y; Guan YY; Zhao F; Yu T; Zhang SJ; Zhang YZ; Duan YC; Zhou XL
Eur J Med Chem; 2022 Mar; 231():114144. PubMed ID: 35093670
[TBL] [Abstract][Full Text] [Related]
32. Targeting EED as a key PRC2 complex mediator toward novel epigenetic therapeutics.
Bao Q; Kumar A; Wu D; Zhou J
Drug Discov Today; 2024 Jun; 29(6):103986. PubMed ID: 38642703
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of polycomb repressive complex 2 by targeting EED protects against cisplatin-induced acute kidney injury.
Yu C; Li T; Li J; Cui B; Liu N; Bayliss G; Zhuang S
J Cell Mol Med; 2022 Jul; 26(14):4061-4075. PubMed ID: 35734954
[TBL] [Abstract][Full Text] [Related]
34. A drug repurposing screening reveals a novel epigenetic activity of hydroxychloroquine.
Catalano R; Rocca R; Juli G; Costa G; Maruca A; Artese A; Caracciolo D; Tagliaferri P; Alcaro S; Tassone P; Amodio N
Eur J Med Chem; 2019 Dec; 183():111715. PubMed ID: 31550663
[TBL] [Abstract][Full Text] [Related]
35. First critical repressive H3K27me3 marks in embryonic stem cells identified using designed protein inhibitor.
Moody JD; Levy S; Mathieu J; Xing Y; Kim W; Dong C; Tempel W; Robitaille AM; Dang LT; Ferreccio A; Detraux D; Sidhu S; Zhu L; Carter L; Xu C; Valensisi C; Wang Y; Hawkins RD; Min J; Moon RT; Orkin SH; Baker D; Ruohola-Baker H
Proc Natl Acad Sci U S A; 2017 Sep; 114(38):10125-10130. PubMed ID: 28864533
[TBL] [Abstract][Full Text] [Related]
36. PRC2 represses transcribed genes on the imprinted inactive X chromosome in mice.
Maclary E; Hinten M; Harris C; Sethuraman S; Gayen S; Kalantry S
Genome Biol; 2017 May; 18(1):82. PubMed ID: 28468635
[TBL] [Abstract][Full Text] [Related]
37. Degradation of Polycomb Repressive Complex 2 with an EED-Targeted Bivalent Chemical Degrader.
Potjewyd F; Turner AW; Beri J; Rectenwald JM; Norris-Drouin JL; Cholensky SH; Margolis DM; Pearce KH; Herring LE; James LI
Cell Chem Biol; 2020 Jan; 27(1):47-56.e15. PubMed ID: 31831267
[TBL] [Abstract][Full Text] [Related]
38. Allosteric Inactivation of Polycomb Repressive Complex 2 (PRC2) by Inhibiting Its Adapter Protein: Embryonic Ectodomain Development (EED).
Yang CY; Wang S
J Med Chem; 2017 Mar; 60(6):2212-2214. PubMed ID: 28256832
[TBL] [Abstract][Full Text] [Related]
39. Structure, mechanism, and regulation of polycomb-repressive complex 2.
Moritz LE; Trievel RC
J Biol Chem; 2018 Sep; 293(36):13805-13814. PubMed ID: 28912274
[TBL] [Abstract][Full Text] [Related]
40. The PRC2 molecule EED is a target of epigenetic therapy for neuroblastoma.
Shaliman D; Takenobu H; Sugino RP; Ohira M; Kamijo T
Eur J Cell Biol; 2022; 101(3):151238. PubMed ID: 35636260
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
